[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"metastatic-lung-carcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:metastatic-lung-carcinoma":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,47,71,94],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100521894","evaluation-of-anti-pd-1-therapy-by-monitoring-t-cell-responses-in-melanoma-lung-and-other-cancer-types-100521894",false,"NCT06075524","Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types","Maximizing Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types","Inclusion Criteria:\n\n* Are 18 years of age or older\n* Have histologic evidence of locally or regionally advanced or stage IV malignancy\n* Are considered appropriate for starting therapy with anti-PD-1\u002Fanti-PD-L1 monoclonal antibody by their treating physician (prior therapy with immune checkpoint inhibitor (ICI) is allowed)\n* Have an understanding of the protocol and its requirements, risks, and discomforts\n* Are willing to undergo peripheral blood collection at the time points mentioned in the protocol\n* Are able and willing to sign an informed consent\n\nExclusion Criteria:\n\n* Inability on the part of the patient to understand the informed consent or be compliant with the protocol\n* Patients receiving any concurrent anti-cancer therapy or investigational agents (with the exception of an anti-PD-1\u002Fanti-PD-L1 agent as mentioned above)\n* Patients who are pregnant, nursing, or are of childbearing potential and are unwilling to employ adequate contraception","ALL","18 Years",{"count":19,"type":20},500,"ESTIMATED","OBSERVATIONAL","This study explores the role of T cells in monitoring disease status and response during anti-PD-1\u002FPD-L1 treatment in patients with melanoma, lung and other cancer types. Measuring levels of specific targets such as Bim and soluble PD-L1 during therapy may help track treatment resistance and clinical outcomes. This information may also help researchers determine why some people with melanoma, lung and other cancer types respond to PD-1\u002FPD-L1 treatment and others do not.",[24,25,26,27,28,29,30,31,32,33],"Clinical Stage III Cutaneous Melanoma AJCC v8","Clinical Stage IV Cutaneous Melanoma AJCC v8","Locally Advanced Lung Carcinoma","Locally Advanced Malignant Solid Neoplasm","Locally Advanced Melanoma","Metastatic Lung Carcinoma","Metastatic Malignant Solid Neoplasm","Metastatic Melanoma","Stage III Lung Cancer AJCC v8","Stage IV Lung Cancer AJCC v8","RECRUITING","2026-06-16",{"date":37,"type":38},"2026-06-18","ACTUAL",{"date":40,"type":38},"2015-06-15",{"date":42,"type":20},"2028-12-31",{"name":44,"class":45},"Mayo Clinic","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":46},"100573209","novel-input-screening-tool-to-improve-illness-understanding-in-patients-with-metastatic-or-incurable-lung-cancer-100573209","NCT06743308","Novel INPUT Screening Tool to Improve Illness Understanding in Patients With Metastatic or Incurable Lung Cancer","Information Needs, Preferences, and Understanding Trial (INPUT): A Randomized, Controlled Trial of the Effects of a Screening Tool on Illness Understanding","Inclusion Criteria:\n\n* Within 3 months of biopsy-confirmed diagnosis of stage IV lung cancer\n* Age 18 or over\n* English speaking\n* Attending a follow-up visit at the thoracic medical oncology clinic\n* Plans to receive or actively undergoing cancer-directed systemic treatment at MD Anderson\n\nExclusion Criteria:\n\n• Diagnosis of cognitive impairment or dementia requiring a surrogate decision maker",{"count":55,"type":20},100,"INTERVENTIONAL",[58],"NA","This clinical trial compares the use of a new screening tool designed to evaluate patients' information needs, preferences, and illness understanding to the usual care to improve illness understanding in patients with lung cancer that has spread from where it first started (primary site) to other places in the body (metastatic) or for which no curative treatment is currently available (incurable). Goal concordant care is a model of care that aligns a patient's medical care with their values, preferences, and goals. Often, patients may not fully understand their illness and prognosis, but this information is important so that they can make fully informed decisions regarding their care that are consistent with their values, preferences, and goals. Completing the Information Needs, Preferences, and Understanding Trial (INPUT) screening tool may allow for more frequent and regular discussions regarding disease status and treatment goals, ultimately resulting in improved patient illness understanding and goal concordant care for patients with metastatic or incurable lung cancer.",[61,29,33],"Lung Carcinoma","2026-04-28",{"date":64,"type":38},"2026-04-29",{"date":66,"type":38},"2024-12-16",{"date":68,"type":20},"2027-12-31",{"name":70,"class":45},"M.D. Anderson Cancer Center",{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":56,"phases":80,"briefSummary":81,"conditions":82,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":46},"100496599","tumor-treating-fields-for-the-treatment-of-leptomeningeal-metastases-of-the-spine-in-patients-with-breast-or-lung-cancer-100496599","NCT05746325","Tumor Treating Fields for the Treatment of Leptomeningeal Metastases of the Spine in Patients With Breast or Lung Cancer","Pilot Feasibility Study of Tumor Treating Fields in Treatment of Leptomeningeal Metastases Involving the Spine","Inclusion Criteria:\n\n* Age \\>= 18\n* Prior tissue diagnosis of breast cancer or lung cancer\n* Confirmed diagnosis of leptomeningeal metastases (LM) with positive cerebrospinal fluid (CSF) cytology for malignancy and meningeal enhancement (type 1A, 1B, and 1C)\n* Radiographic evidence on MRI of leptomeningeal enhancement within the cervical, thoracic or lumbar spine on spinal MRI\n* Life expectancy of at least 6 weeks\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, 2, or 3\n* Recovery from any neurotoxic effects of prior therapy\n* Platelet count greater than 25 x 10\\^9\u002FL\n* Absolute neutrophil count (ANC) greater than 0.5 x 10\\^9\u002FL\n* Patients must have adequate liver function, total bilirubin \\\u003C 2.5 mg\u002FdL, unless elevated total bilirubin is due to elevated indirect bilirubin from known Gilbert's disease, aspartate aminotransferase (AST) =\\\u003C 3.5 times upper limits of normal; adequate renal function \\[calculated estimated glomerular filtration rate (eGFR) \\>= 30 mL\u002Fmin\u002F body surface area (BSA)\\]\n* Patients or legal medical representative must provide written informed consent\n* Patients must have suitable body habitus for placement of transducer arrays\n* Patients must be willing to wear the device for at least 18 hours a day (averaged over monthly)\n* Patients must be willing to return for the scheduled evaluations and perform the required assessments\n* Patients are without other disease or situation which would significantly compromise adequate assessment of safety and feasibility of the TTF\n* Patient willing to start a study treatment with TTF =\\\u003C 14 days from registration\n\nExclusion Criteria:\n\n* Concomitant therapy:\n\n  * Must not be receiving concurrent high-dose methotrexate (\\>= 3 g\u002Fm\\^2), high dose thiotepa, or high-dose cytarabine (\\>= 3 g\u002Fm\\^2). Any other systemic chemotherapy, targeted treatment, hormonal or immunotherapy directed at the primary systemic malignancy is permitted\n  * Must not have received radiation therapy (RT) to the brain or spinal cord within 2 weeks of initiation of TTF\n  * Must be at least 1 week from cessation of any prior intrathecal chemotherapy\n* Women of childbearing age who are pregnant or lactating. (Male and female patients who are fertile must be willing to use an effective means of birth control to avoid pregnancy)\n* Patients with uncontrolled or untreated infection including active hepatitis, and human immunodeficiency virus (HIV)\n* Patients receiving any other investigational agents and must not have received any other investigational agent within 14 days prior to registration. The 14-day period should be extended if the investigational agent is known to have delayed toxicity\n* Patients known to be allergic to the hydrophilic gel utilized for transducer attachment\n* Patients with surgical hardware within the planned area of treatment in the spine (e.g., titanium rods, screws, fixation devices)",{"count":79,"type":20},5,[58],"This clinical trial evaluates the safety and feasibility of tumor treating fields (TTF) in the treatment of spinal leptomeningeal disease in patients with breast or lung cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Patients wear the portable Novo TTF-200T device that produces electric fields to target areas on the body to stop the growth of tumor cells. The information from this study will help researchers develop a better treatment for leptomeningeal metastases in the future.",[83,84,85,29,33],"Anatomic Stage IV Breast Cancer AJCC v8","Metastatic Breast Carcinoma","Metastatic Malignant Neoplasm in the Leptomeninges","2026-03-31",{"date":88,"type":38},"2026-04-02",{"date":90,"type":38},"2023-04-07",{"date":92,"type":20},"2027-03-01",{"name":44,"class":45},{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":101,"targetDuration":4,"studyType":56,"phases":103,"briefSummary":105,"conditions":106,"keywords":108,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":124},"100631408","phase-2-yittrium-90y-90-fibroblast-activation-protein-inhibitor-fapi-therapy-in-patients-with-non-small-cell-lung-cancer-phase-ii-100631408","NCT07500285","Yittrium-90(Y-90) Fibroblast Activation Protein Inhibitor (FAPI) Therapy in Patients With Non-Small Cell Lung Cancer (Phase II)","A Novel Therapeutic Target in Non-Small Cell Lung Cancer: Evaluation of the Efficacy of Yttrium-90 (Y-90) Fibroblast Activation Protein Inhibitor (FAPI) - A Phase II Study","Inclusion Criteria:\n\n* Age ≥18 years\n* Histologically confirmed diagnosis of non-small cell lung cancer (NSCLC)\n* Metastatic disease\n* Prior staging with F-18 FDG PET\u002FCT\n* Ga-68 FAPI PET\u002FCT demonstrating increased tracer uptake in tumor lesions (SUVmax ≥10 in more than 50% of metastatic lesions)\n* Disease progression or resistance after all standard approved therapies as determined by a multidisciplinary tumor board\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-2\n* Adequate organ function:\n* Serum creatinine ≤150 μmol\u002FL\n* Hemoglobin ≥8.0 g\u002FdL\n* White blood cell count ≥2.0 × 10⁹\u002FL\n* Platelet count ≥50 × 10⁹\u002FL\n* Total bilirubin ≤3 × upper limit of normal\n* Serum albumin ≥2.0 g\u002FdL\n* Ability to understand and willingness to sign written informed consent\n\nExclusion Criteria:\n\n* Age \\\u003C18 years\n* Diagnosis of small cell lung cancer\n* History of another active malignancy\n* Pregnancy or breastfeeding\n* Severe uncontrolled medical illness that would interfere with study participation\n* Refusal or inability to provide written informed consent",{"count":102,"type":20},10,[104],"PHASE2","Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related mortality worldwide and accounts for approximately 80% of all lung cancer cases. Despite advances in chemotherapy, radiotherapy, and immunotherapy, the prognosis of patients with advanced-stage metastatic NSCLC remains poor, with limited therapeutic options after the development of treatment resistance.\n\nFibroblast Activation Protein (FAP) is highly expressed in cancer-associated fibroblasts in a wide range of solid tumors and represents a promising target for tumor-specific theranostic approaches. Gallium-68-labeled FAPI (Ga-68 FAPI) PET\u002FCT has recently demonstrated high sensitivity in imaging primary lung tumors and metastatic lesions.\n\nThis Phase II study aims to evaluate the safety, feasibility, dosimetry, and therapeutic efficacy of Yttrium-90-labeled FAPI (Y-90 FAPI) radionuclide therapy in patients with chemotherapy-resistant metastatic NSCLC showing significant FAP expression on Ga-68 FAPI PET\u002FCT imaging.",[107,29],"Non-Small Cell Lung Cancer",[109,110,111,112,113,114],"non-small cell lung cancer","Fibroblast Activation Protein","Yttrium-90 FAPI","Targeted Radionuclide Therapy","Phase II Clinical Trial","90Y-FAPI Radioligand Therapy","NOT_YET_RECRUITING","2026-03-28",{"date":86,"type":38},{"date":119,"type":20},"2026-04-10",{"date":121,"type":20},"2027-11-15",{"name":123,"class":45},"Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization",2]